Table: Towa Pharmaceutical -2017/18 parent results
May 14 (Reuters)-
Towa Pharmaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2018 Mar 31, 2017 Mar 31, 2019 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 90.99 82.72
(+10.0 pct) (+3.3 pct)
Operating 12.11 7.77
(+55.8 pct) (-35.4 pct)
Recurring 8.83 8.35
(+5.6 pct) (-21.8 pct)
Net 5.48 6.65
(-17.7 pct) (-19.4 pct)
EPS 334.08 yen 405.71 yen
EPS Diluted 308.79 yen 375.08 yen
Ann Div 95.00 yen 95.00 yen 95.00 yen
-Q2 Div 47.50 yen 47.50 yen 47.50 yen
-Q4 Div 47.50 yen 47.50 yen 47.50 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results